DAYONIX PHARMA LIMITED
Company number 11535316 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Assessment: DAYONIX PHARMA LIMITED
1. Financial Health Score: F
Explanation: The company is in a state of chronic insolvency. Net liabilities have worsened every year since incorporation, reaching £684,254 in negative equity as of August 2024. The business is entirely dependent on creditor financing to remain operational, with liabilities exceeding assets by a substantial and growing margin. This is a patient in critical condition requiring urgent intervention.
2. Key Vital Signs
| Vital Sign | 2024 | 2023 | Trend | Interpretation |
|---|---|---|---|---|
| Net Assets | (£684,254) | (£621,995) | ⬇ Deteriorating | Deepening insolvency – the "blood loss" is accelerating |
| Current Assets | £445,492 | £202,400 | ⬆ Improving | Asset growth, but funded entirely by debt |
| Current Liabilities | (£1,238,898) | (£797,371) | ⬇ Worsening | 55% increase in short-term debts – a dangerously high pulse rate |
| Net Current Liabilities | (£663,096) | (£594,971) | ⬇ Deteriorating | No working capital – the business cannot cover near-term obligations |
| Shareholders' Funds | (£684,254) | (£621,995) | ⬇ Worsening | Equity is deeply negative – the "immune system" is compromised |
| Share Capital | £167 | £167 | ➡ Flat | Minimal equity investment by shareholders |
| Employees | 3 | 3 | ➡ Stable | Small workforce |
Historical Progression of Net Assets:
| Year | Net Assets | Annual Deterioration |
|---|---|---|
| 2019 | (£127,009) | — |
| 2020 | (£382,217) | (£255,208) |
| 2021 | (£512,047) | (£129,830) |
| 2022 | (£593,652) | (£81,605) |
| 2023 | (£621,995) | (£28,343) |
| 2024 | (£684,254) | (£62,259) |
3. Diagnosis
Condition: Chronic Insolvency with Progressive Deterioration
The financial data reveals a business that has been technically insolvent throughout its entire observable history. Since incorporation in 2018, the company has never held positive net assets. This is not a temporary cash flow problem – it is a structural condition where liabilities consistently and significantly exceed assets.
Symptoms Analysis:
🚨 Symptom 1: Negative Equity Spiral Net liabilities have grown from £127,009 (2019) to £684,254 (2024) – a 438% deterioration over five years. This indicates the business consistently spends more than it earns, with losses accumulating in the P&L reserve and eroding any possibility of recovery without significant external intervention.
🚨 Symptom 2: Extreme Leverage Dependency With only £167 in share capital against £1.24M in liabilities, the company is operating on a leverage ratio that would be considered fatal in any conventional assessment. The business is entirely sustained by creditor financing – likely including director loans, trade creditors, and potentially related-party debts.
⚠️ Symptom 3: Asset Growth Masked by Debt Growth While current assets grew from £202,400 to £445,492 (a 120% increase), this was entirely funded by a corresponding increase in current liabilities from £797,371 to £1,238,898 (a 55% increase). This is akin to gaining weight through water retention rather than muscle – the apparent growth is unhealthy.
⚠️ Symptom 4: No Fixed Assets The company holds virtually no fixed assets (£0 in 2024, £171 in 2023), meaning there is no asset base to secure against or liquidate in a distress scenario. The business has no "bone structure" to support recovery.
ℹ️ Symptom 5: Prepayments Anomaly The appearance of £130,310 in prepayments and accrued income in 2024 (nil in 2023) may indicate advance payments for inventory or services – potentially a positive trading signal, but within the context of deepening insolvency, it raises questions about whether these represent commitments the company may struggle to fulfil.
Potential Underlying Causes:
- The company may be in a pre-revenue or early commercialization phase (pharmaceutical/dietetic food development typically requires significant upfront investment)
- Operations may be funded primarily through director/shareholder loans that appear as liabilities
- The business model may require sustained capital investment before reaching profitability
- There may be related-party or group financing structures not visible in micro-entity accounts
4. Recommendations
Immediate Actions (Critical):
1. Conduct a Solvency Assessment The directors must urgently assess whether the company can pay its debts as they fall due. Under the Insolvency Act 1986, directors have a duty to act when they know (or should know) that there is no reasonable prospect of avoiding insolvent liquidation. Continuing to trade while insolvent carries personal liability risks.
2. Clarify the Liability Composition Micro-entity accounts provide minimal disclosure. The directors should prepare a detailed breakdown of the £1.24M in liabilities to understand: - How much is owed to directors/shareholders (related party loans)? - How much is trade creditor debt? - Are there any contingent liabilities not on the balance sheet?
3. Secure Written Creditor Support If the business is dependent on director loans or related-party funding, these creditors should formalize their commitment not to demand repayment. Written declarations of support can provide evidence of going concern viability.
Medium-Term Actions (Important):
4. Develop a Credible Path to Profitability The company needs a clear, documented route to positive net assets. This should include: - Revenue projections with realistic timelines - Cost reduction strategies - Break-even analysis and milestones
5. Consider Capital Restructuring With only £167 in share capital, the owners should consider: - Converting director loans to equity (capitalizing debt) - Issuing new shares to inject permanent capital - This would improve the balance sheet and reduce the insolvency gap
6. Explore Funding Alternatives Given the industry (pharmaceutical/dietetic food manufacturing), investigate: - Grant funding or R&D tax credits - Strategic investment partnerships - Asset-based lending if viable assets are acquired
Ongoing Monitoring:
7. Monthly Cash Flow Forecasting With net current liabilities of £663,096, the company has zero margin for error. Monthly rolling cash flow forecasts should be maintained and reviewed by the board.
8. Regular Director Reviews of Going Concern Given the persistent insolvency, the directors should formally review going concern status at least quarterly, documenting their assessment and the basis for their judgment.
Risk Assessment Summary
| Risk Factor | Severity | Likelihood |
|---|---|---|
| Insolvent liquidation | Critical | High |
| Director personal liability (wrongful trading) | High | Medium-High |
| Creditor action/demand | High | Medium |
| Inability to meet obligations as they fall due | Critical | High |
| Reputational damage to directors | Medium | Medium |
Important Caveat: Micro-entity accounts provide extremely limited financial information. The picture presented here may be distorted if significant liabilities represent director/shareholder loans that are subordinated or unlikely to be called. A full review of the company's books, records, and creditor composition would be necessary before reaching definitive conclusions about viability.